Jim Cramer, the host of CNBC’s “Mad Money,” is known for his energetic and often controversial takes on the stock market.

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

The union members, most of them based in Washington state, turned down a proposal to raise wages by 25% over four years, as ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.8, a high ...

FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

NovaBay shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets ...

Gartner IT has outperformed the market over the past 15 years by 13.06% on an annualized basis producing an average annual ...

Onchain analytics firm Lookonchain identified an Ethereum (CRYPTO: ETH) whale losing $13 million in the past six months as ...

Today, Benzinga's options scanner spotted 12 options trades for SoFi Techs. This is not a typical pattern. The sentiment ...